SCHEMBL2573283

SCHEMBL2573283

CC(C)(C)c1nc(-c2cccc3ccccc23)cn1CC1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 13/20 0.42
CNR2 P34972 9/20 0.42
TLR8 Q9NR97 1/20 0.40
HTR2C P28335 1/20 0.39
KCNH2 Q12809 7/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2568534 0.83 CNR2 (0.47) CNR1CNR2KCNH2
SCHEMBL2574267 0.83 CNR1 (0.41) CNR1CNR2KCNH2
SCHEMBL2571603 0.81 CNR2 (0.43) CNR1CNR2
SCHEMBL2568600 0.80 CNR2 (0.49) CNR1CNR2KCNH2
SCHEMBL2572513 0.79 CNR2 (0.38) CNR1CNR2KCNH2
SCHEMBL2569941 0.79 CNR2 (0.40) CNR1CNR2
SCHEMBL2570055 0.79 CNR2 (0.40) CNR1CNR2
SCHEMBL2569711 0.78 CNR2 (0.39) CNR1CNR2KCNH2
SCHEMBL2572449 0.78 CNR2 (0.40) CNR1CNR2
SCHEMBL2569085 0.77 CNR2 (0.42) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289502-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-15 US disclosed
US-8273738-B2 Imidazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-09-25 US disclosed
EP-2090570-B1 IMIDAZOLE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2011-11-09 EP disclosed
US-20100152178-A1 IMIDAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 US disclosed
EP-2090570-A1 IMIDAZOLE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289502-A1 IMIDAZOLE DERIVATIVES CNR1, CNR2, ARRB1 CNR1 1/4885CNR2 2/4885TLR8 462/4885
US-20100152178-A1 IMIDAZOLE DERIVATIVES CNR1, CNR2, ARRB1 CNR1 1/4885CNR2 2/4885TLR8 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.